Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration

Research output: Contribution to journalArticlepeer-review

Standard

Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration. / Clark, Andrew R.; Ohlmeyer, Michael.

In: Pharmacology & Therapeutics, Vol. 201, 30.09.2019, p. 181-201.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{7d0a709c2a0d43e2ad3da7e7d7b358d0,
title = "Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration",
abstract = "Protein phosphatase 2A (PP2A) is a highly complex heterotrimeric enzyme that catalyzes the selective removal of phosphate groups from protein serine and threonine residues. Emerging evidence suggests that it functions as a tumor suppressor by constraining phosphorylation-dependent signalling pathways that regulate cellular transformation and metastasis. Therefore, PP2A-activating drugs (PADs) are being actively sought and investigated as potential novel anti-cancer treatments. Here we explore the concept that PP2A also constrains inflammatory responses through its inhibitory effects on various signalling pathways, suggesting that PADs may be effective in the treatment of inflammation-mediated pathologies.",
keywords = "Protein phosphatase 2A, Inflammation, Cancer, Neurodegeneration, Alzheimer{\textquoteright}s disease, Multiple sclerosis",
author = "Clark, {Andrew R.} and Michael Ohlmeyer",
year = "2019",
month = sep,
day = "30",
doi = "10.1016/j.pharmthera.2019.05.016",
language = "English",
volume = "201",
pages = "181--201",
journal = "Pharmacology & Therapeutics",
issn = "0163-7258",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration

AU - Clark, Andrew R.

AU - Ohlmeyer, Michael

PY - 2019/9/30

Y1 - 2019/9/30

N2 - Protein phosphatase 2A (PP2A) is a highly complex heterotrimeric enzyme that catalyzes the selective removal of phosphate groups from protein serine and threonine residues. Emerging evidence suggests that it functions as a tumor suppressor by constraining phosphorylation-dependent signalling pathways that regulate cellular transformation and metastasis. Therefore, PP2A-activating drugs (PADs) are being actively sought and investigated as potential novel anti-cancer treatments. Here we explore the concept that PP2A also constrains inflammatory responses through its inhibitory effects on various signalling pathways, suggesting that PADs may be effective in the treatment of inflammation-mediated pathologies.

AB - Protein phosphatase 2A (PP2A) is a highly complex heterotrimeric enzyme that catalyzes the selective removal of phosphate groups from protein serine and threonine residues. Emerging evidence suggests that it functions as a tumor suppressor by constraining phosphorylation-dependent signalling pathways that regulate cellular transformation and metastasis. Therefore, PP2A-activating drugs (PADs) are being actively sought and investigated as potential novel anti-cancer treatments. Here we explore the concept that PP2A also constrains inflammatory responses through its inhibitory effects on various signalling pathways, suggesting that PADs may be effective in the treatment of inflammation-mediated pathologies.

KW - Protein phosphatase 2A

KW - Inflammation

KW - Cancer

KW - Neurodegeneration

KW - Alzheimer’s disease

KW - Multiple sclerosis

U2 - 10.1016/j.pharmthera.2019.05.016

DO - 10.1016/j.pharmthera.2019.05.016

M3 - Article

C2 - 31158394

VL - 201

SP - 181

EP - 201

JO - Pharmacology & Therapeutics

JF - Pharmacology & Therapeutics

SN - 0163-7258

ER -